We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.87%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$833M
AUM Growth
+$240M
Cap. Flow
+$158M
Cap. Flow %
18.98%
Top 10 Hldgs %
35.14%
Holding
103
New
14
Increased
42
Reduced
34
Closed
7

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$19.1M
2
UNH icon
UnitedHealth
UNH
+$11.9M
3
COO icon
Cooper Companies
COO
+$7.39M
4
ESRX
Express Scripts Holding Company
ESRX
+$6.9M
5
MDT icon
Medtronic
MDT
+$6.56M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$4.81M
2
OCR
OMNICARE INC
OCR
+$3.85M
3
GILD icon
Gilead Sciences
GILD
+$3.17M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$3.01M
5
MCK icon
McKesson
MCK
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 76.95%
2 Financials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
26
Elevance Health
ELV
$85.5B
$9.52M 1.14%
58,000
+1,000
+2% +$160K
UHS icon
27
Universal Health Services
UHS
$10.5B
$9.24M 1.11%
65,000
-22,000
-25% -$2.76M
ESPR
28
DELISTED
Esperion Therapeutics
ESPR
$9.16M 1.1%
112,000
-14,926
-12% -$1.46M
PRGO icon
29
Perrigo
PRGO
$1.78B
$8.69M 1.04%
47,000
+27,000
+135% +$5.15M
BDX icon
30
Becton Dickinson
BDX
$48.2B
$8.5M 1.02%
61,500
+13,343
+28% +$1.84M
LH icon
31
Labcorp
LH
$25.9B
$8.48M 1.02%
81,480
+36,084
+79% +$3.76M
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$5.03B
$8M 0.96%
191,000
+20,000
+12% +$774K
ALNY icon
33
Alnylam Pharmaceuticals
ALNY
$29.3B
$7.36M 0.88%
61,400
+8,400
+16% +$1M
DXCM icon
34
DexCom
DXCM
$32B
$7.36M 0.88%
368,000
+60,000
+19% +$1.05M
COO icon
35
Cooper Companies
COO
$14.5B
$7.3M 0.88%
+164,000
New +$7.39M
BHC icon
36
Bausch Health
BHC
$2.34B
$7.16M 0.86%
32,248
-3,752
-10% -$832K
SUPN icon
37
Supernus Pharmaceuticals
SUPN
$2.77B
$7.08M 0.85%
417,000
-33,800
-7% -$481K
ESRX
38
DELISTED
Express Scripts Holding Company
ESRX
$7.03M 0.84%
+79,000
New +$6.9M
CYH icon
39
Community Health Systems
CYH
$423M
$6.93M 0.83%
133,100
-9,680
-7% -$434K
ABMD
40
DELISTED
Abiomed Inc
ABMD
$6.84M 0.82%
104,000
+49,000
+89% +$3.26M
VRTX icon
41
Vertex Pharmaceuticals
VRTX
$126B
$6.79M 0.82%
55,000
-3,000
-5% -$378K
ITCI
42
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.58M 0.79%
206,000
+23,000
+13% +$583K
AET
43
DELISTED
Aetna Inc
AET
$6.5M 0.78%
51,000
+10,000
+24% +$1.14M
HCA icon
44
HCA Healthcare
HCA
$89.5B
$6.26M 0.75%
69,000
-5,000
-7% -$401K
STJ
45
DELISTED
St Jude Medical
STJ
$6.07M 0.73%
83,000
+34,200
+70% +$2.47M
CYBX
46
DELISTED
CYBERONICS INC
CYBX
$5.95M 0.71%
100,000
-8,000
-7% -$504K
ICPT
47
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$5.79M 0.7%
24,000
+1,000
+4% +$266K
CERN
48
DELISTED
Cerner Corp
CERN
$5.73M 0.69%
83,000
+17,000
+26% +$1.19M
VTRS icon
49
Viatris
VTRS
$18.9B
$5.63M 0.68%
+83,000
New +$5.87M
MCK icon
50
McKesson
MCK
$101B
$5.62M 0.67%
25,000
-13,000
-34% -$3.01M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Rhenman & Partners Asset Management held 103 positions worth $833M, up 40% from $593M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management deployed $158M of net new capital in Q2 2015, opening 14 new positions and adding to 42 existing holdings. Its largest new stake was Johnson & Johnson: 191,000 shares worth $18.6M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Amgen, an estimated $4.81M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2015 buy was Johnson & Johnson: 191,000 shares worth $18.6M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2015, an estimated $11.9M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2015 reduction was Amgen, cutting an estimated $4.81M.
  • Rhenman & Partners Asset Management fully exited OMNICARE INC in Q2 2015, selling an estimated $3.85M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $833M portfolio in Q2 2015.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 7 in Q2 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 40% quarter-over-quarter to $833M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2015, filed 30 Jul 2015.